Kazia Therapeutics Ltd ADR美股招股说明书（2026年3月19日版）

Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December23, 2025 (the“Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No.333-292303), with the information contained in ourcurrent report on Form 6-K, furnished to the Securities and Exchange Commission on March19, 2026 (the “March 19, 2026 Form 6-K”). Accordingly, This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered orutilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On March18, 2026, the last reported sale price of the ADSson Nasdaq was $7.51 per ADS. Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 of the Prospectus andthe “Risk Factors” in “Item 3. Key Information-D. Risk Factors” of our most recent Annual Report on Form 20-F,which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passedupon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. The date of this prospectus supplement is March19, 2026 INFORMATION CONTAINED IN THIS FORM 6-K REPORT On March16, 2026 AEDT, Kazia Therapeutics Limited (the “Company”) reported its unaudited half-year results for the sixmonths endedDecember31, 2025, a copy of which is attached to this Form 6-K as Exhibit 99.1. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, into the Company’s registrationstatements on Form F-3 (File No.333-281937). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by theundersigned, thereunto duly authorized. Kazia Therapeutics Limited(Registrant) Date: March19, 2026 Kazia Therapeutics LimitedDirectors’ report The directors present their report, together with the financial statements, on the Consolidated entity (referred to hereafter as the ‘Consolidated entity’)consisting of Kazia Therapeutics Limited (referred to hereafter as the ‘Consolidated entity’ or ‘parent entity’) and the entities it controlled at the end of,or during, the half-year ended 31December 2025. Directors The following persons were directors of Kazia Therapeutics Limited during the whole of the financial year and up to the date of this report, unlessotherwise stated: Dr John FriendBryce CarmineSteven Coffey Principal activities During the financial year the principal continuing activity of the Consolidated entity consisted of pharmaceutical research and development with a viewto commercialising the results of our research through license transactions or other means. Review of operations The loss for the Consolidated entity after providing for income tax amounted to $12,552,490 (31December 2024: $10,453,811). The attached financial statements detail the performance and financial position of the Consolidated entity for the half-year ended 31December 2025. Cash resources At 31December 2025, the Consolidated entity had total funds of $69,459,980 comprising cash in hand and at bank. Going concern For the period ended 31December 2025 the Consolidated Entity incurred a loss after income tax of $12,552,490 (31December 2024: $10,453,811), wasin a net current asset position of $45,612,689 (30June 2025 net current liability: $9,119,727) and had net cash outflows from operating activities of$9,540,623 (31December 2024: $8,420,244) for the half-year ended 31December 2025. The Directors note the following with regards to the ability of the Consolidated Entity to continue as a going concern: •During the period, the Company received notifications from Nasdaq regarding non-compliance with the minimum Market Value ofListed Securities requirement. On 18December 2025, the Nasdaq Office of General Counsel confirmed that the Company had •The Consolidated Entity continued to access capital markets during the period. Capital raised in the period, including the PIPEentered on 2nd December 2025 which raised US$46.51million after deducting offering expenses has resulted in a cash balance ofAUD 69.46million at 31December 2025. The Directors have considered the Consolidated Entity’s cash flow forecasts for a period Accordingly, the financial statements have been prepared on a going concern basis which assumes continuity of normal activities and the realisation ofassets and the settlement of liabilities in the ordinary course of business. Kazia Therapeutics Li